CD44 and MMP9 are frequently utilized as immunohistochemical markers that are concurrently evaluated in renal cell carcinoma (RCC) and have been identified as potential molecular prognostic markers for RCC [17]. The gene discussed is CD44; the disease is renal cell carcinoma.